Sub menu

Vaccination for special risk groups

Vaccination for women who are planning pregnancy, pregnant or breastfeeding

Giving recommended vaccines before, during and after pregnancy protects both the mother and the baby.

Recently added

This page was added on 08 June 2018.

Updates made

This page was updated on 13 March 2026. View history of updates

On this page

Overview

Pregnant women are at increased risk of certain vaccine preventable diseases such as Influenza which can lead to pregnancy complications and poor health outcomes in their infant. Vaccination during pregnancy does not only protect the mother but also generates antibodies that can cross the placenta, providing protection to the unborn baby and immunity that may persist for several months after birth, which is important for preventing diseases such as pertussis in infants too young to be vaccinated.1,2 Women who are planning pregnancy, pregnant or breastfeeding are therefore recommended to have their vaccination needs assessed e.g., as part of their pre-conception screen, and to receive certain vaccines during their pregnancy.

Women planning pregnancy

Women planning pregnancy should have their vaccination needs assessed as part of any pre-conception health check. In particular, consider vaccines for:

  • hepatitis B
  • measles
  • mumps
  • rubella
  • varicella
  • COVID-19

It is also important to ask women of child-bearing age who present for vaccination about the possibility of pregnancy as part of routine pre-vaccination screening. This is so that they are not given any vaccines that are not recommended in pregnancy (see Pre-vaccination screening). Advise women who receive live vaccines to avoid pregnancy within 28 days of vaccination. However, it is important to note that this is based on vaccine product information and not supported by clinical data.

Serological testing

If a woman’s vaccination or infection history is uncertain, she can have serological testing to determine immunity to:

  • hepatitis B
  • measles
  • mumps
  • rubella

Routine serological testing for varicella does not provide a reliable measure of vaccine-induced immunity, although it can indicate whether the woman has immunity through natural infection (see Varicella).

Assess women with risk factors for pneumococcal disease, including smokers, and Aboriginal and Torres Strait Islander women, for pneumococcal vaccination.

See also Pneumococcal disease for more details about vaccination requirements.

Pregnant women

Recommended vaccines for pregnant women

Pregnant women are routinely recommended to receive:

  • inactivated influenza vaccine, at any time during pregnancy
  • pertussis-containing vaccine (dTpa — reduced antigen diphtheria-tetanus-acellular pertussis), between mid 2nd trimester and early 3rd trimester (preferably between 20 and 32 weeks gestation)
  • respiratory syncytial virus (RSV) vaccine (Abrysvo only) from 28 weeks gestation (preferably between 28 and 36 weeks gestation)

See Table. Vaccines that are routinely recommended in pregnancy: inactivated vaccines.

See also the disease-specific chapters in this Handbook for more details.

Coadministration of vaccines in pregnancy

Influenza, dTpa and RSV vaccines can be given at the same time or separate to each other. If these vaccines are co-administered, they should be administered in alternate sites.  

Table. Vaccines that are routinely recommended in pregnancy: inactivated vaccines

See also the disease-specific chapters in this Handbook for more details.

Vaccine Recommendation Comments
Influenza (inactivated) Recommended as a single dose for all pregnant women at any stage of pregnancy, particularly those who will be in the 2nd or 3rd trimester during the influenza season Clinical trial data and observational studies show no increased risk of congenital defects or adverse effects in the fetuses of women who received influenza vaccine during pregnancy. Pregnancy increases the risk of severe influenza. Influenza immunisation protects the mother, and also protects her newborn baby in the first few months after birth.2 Inactivated influenza vaccines should be given in pregnancy instead of live attenuated influenza vaccines (LAIV). See Influenza.
dTpa (diphtheria-tetanus-acellular pertussis) Recommended as a single dose between mid 2nd trimester and early 3rd trimester of each pregnancy (ideally at 20–32 weeks) Vaccination during pregnancy reduces the risk of pertussis in pregnant women and their young infants by 90%.2,3 Studies have found no evidence of an increased risk of adverse pregnancy outcomes related to pertussis vaccination during pregnancy.4-9 Optimal protection is provided when the vaccine is given soon after 20 weeks and protection is lower if given within 2 weeks of birth. See Pertussis for more details.
Respiratory syncytial virus (Abrysvo only) Recommended as a single dose from 28 weeks gestation (preferably between 28 and the end of 36 weeks gestation) in each pregnancy.

A clinical trial found vaccine efficacy of 57% in infants born to mothers who received Abrysvo, against hospitalisation from RSV for up to 6 months.10 Post-licensure effectiveness data from the UK and Argentina, show a 72% to 82% reduction in the incidence of RSV-related lower respiratory tract infection hospitalisation, among infants during their first 6 months of life.11-14

There was no conclusive evidence of a significant difference in preterm births or other adverse pregnancy outcomes in the Abrysvo trials. Vaccination before 28 weeks is not recommended, as a precautionary approach due to an imbalance in the number of preterm births and neonatal deaths seen in low- and middle-income countries during another discontinued maternal RSV vaccine trial.15 Vaccination beyond 36 weeks is permitted; however, protection is lower if given within 2 weeks of birth. The recommendation for revaccination in subsequent pregnancies is based on immunologic principles and experience with other vaccines recommended in pregnancy as there is currently limited evidence.  See respiratory syncytial virus (RSV) for more details.
Table. Vaccines that are not routinely recommended in pregnancy: inactivated bacterial vaccines
Vaccine Recommendation Comments
dT (diphtheria-tetanus) Not routinely recommended as a dT only vaccine. Pregnant women can receive dT vaccine under certain circumstances, such as to manage a tetanus-prone wound, however depending on timing during pregnancy, a dTpa may be a preferred option (see Pertussis). Many pregnant women have received tetanus- and diphtheria-containing vaccines, with no increased risk of congenital abnormalities in their fetuses.16-18 See Diphtheria and Tetanus for more details.
Cholera (oral) Not routinely recommended There are limited data on the safety of oral cholera vaccine in pregnancy.2,19
Hib (Haemophilus influenzae type b) Not routinely recommended. Pregnant women can receive Hib vaccine if they are at increased risk of Hib disease (eg women with asplenia). Limited data suggest that Hib vaccination during pregnancy is unlikely to harm the fetus.20
MenB (meningococcal B) or MenACWY (quadrivalent meningococcal conjugate) Not routinely recommended. Pregnant women can receive meningococcal vaccines if they are at increased risk of the disease (see Meningococcal disease). There are limited data on the safety of meningococcal conjugate vaccines in pregnancy.21 Where clinically indicated, pregnant women can receive these vaccines.2,22
Pneumococcal conjugate vaccine (PCV) Not routinely recommended. Pregnant women can receive 13vPCV, 15vPCV or 20vPCV if they have very high risk of invasive pneumococcal disease (IPD) (e.g. those who do not have a spleen or evidence of reduced splenic function, or immunocompromised, or have cerebrospinal fluid leak) (see Pneumococcal disease). No data are available. Vaccination with 13vPCV, 15vPCV or 20vPCV during pregnancy has not been evaluated, although it is unlikely to result in adverse effects. Women of child-bearing age with known risk factors for IPD (including smokers) can receive the vaccine before pregnancy or as soon as practicable after birth (see Pneumococcal disease).
23vPPV (23-valent pneumococcal polysaccharide) Not routinely recommended. Pregnant women can receive 23vPPV if they have very high risk of IPD (e.g. those who do not have a spleen or evidence of reduced splenic function, or immunocompromised, or have cerebrospinal fluid leak) (see Pneumococcal disease). Pregnant women have received 23vPPV during clinical trials23 with no evidence of adverse effects. However, data are limited. Women of child-bearing age with known risk factors for IPD (including smokers) can receive the vaccine before pregnancy or as soon as practicable after birth (see Pneumococcal disease).
Q fever Not routinely recommended No data available.
Typhoid Vi polysaccharide Not routinely recommended. Pregnant women can receive typhoid Vi polysaccharide vaccine if they are travelling to endemic countries where water quality and sanitation are poor. No data are available.24 Vaccination with typhoid Vi polysaccharide vaccine during pregnancy has not been directly evaluated, although it is unlikely to result in adverse effects.
Table. Vaccines that are not routinely recommended in pregnancy: inactivated viral vaccines
Vaccine Recommendation Comments
COVID-19 Not routinely recommended in previously vaccinated women, but can be considered on an individual basis. Unvaccinated women are recommended to receive COVID-19 vaccine. Vaccine can be given at any stage of pregnancy. Safe use of mRNA COVID-19 vaccines in pregnancy has been demonstrated.25 See COVID-19.
Hepatitis A

Not routinely recommended. Pregnant women can receive hepatitis A vaccine if:

  • they are travelling to areas of moderate to high endemicity
  • they have increased risk of exposure through lifestyle factors or exposure to a person known to have acute hepatitis A
  • severe outcomes may be expected (eg women with pre-existing liver disease)
 Limited data are available. Pregnant women who are non-immune and at increased risk for hepatitis A should receive hepatitis A vaccine.2,26
Hepatitis B Not routinely recommended. Susceptible pregnant women can receive hepatitis B vaccine if it would otherwise be recommended (eg as post-exposure prophylaxis in a non-immune pregnant woman after a significant exposure to hepatitis B). Limited data are available. Women who are non-immune and at increased risk for hepatitis B should receive hepatitis B vaccine.27
Mpox vaccine (JYNNEOS) Not routinely recommended. Post-exposure preventive vaccination during pregnancy may be considered after a risk–benefit assessment.

MVA-BN mpox vaccine has not been formally evaluated in pregnant or lactating women, but limited animal studies have identified no vaccine-related fetal malformations. No adverse events have been reported from use of MVA-BN in pregnant women, though data are limited to fewer than 300 pregnancies.28  

Post-exposure preventive vaccination during pregnancy may be considered after a risk–benefit assessment. Any decision on the use of vaccine should take into account the likelihood of mpox disease in pregnancy, and the risks to both the mother and fetus.
Japanese encephalitis (JE) (JEspect inactivated vaccine) Not routinely recommended. Pregnant women at high risk of acquiring JE can receive inactivated JE vaccine. Limited data are available. JE infection is associated with miscarriage. Assess whether pregnant women who are at high risk of JE need vaccination. If the risk of JE is high, pregnant women should receive the inactivated vaccine, JEspect (not Imojev, which is a live attenuated vaccine).2,29
IPV (inactivated poliovirus) Not routinely recommended. Pregnant women at high risk of poliovirus exposure (eg travelling to endemic countries) can receive IPV vaccine. Limited data suggest that polio vaccination during pregnancy is unlikely to harm the fetus.24 Pregnant women should receive IPV vaccine only when clearly indicated.
Rabies Pregnant women can receive rabies vaccine if required, such as for post-exposure prophylaxis. Limited data suggest that rabies vaccination during pregnancy is unlikely to harm the fetus.30-33 Pregnancy is never a contraindication to rabies vaccination if there is a significant risk of exposure (related to occupation or travel), or if there has been a potential exposure to rabies virus, Australian bat lyssavirus or another bat lyssavirus.2,34,35
Zoster (recombinant zoster vaccine [Shingrix]) Not routinely recommended. Pregnant women at high risk of severe outcomes from herpes zoster (eg severe immunocompromise) can receive Shingrix. There are no data on the use of Shingrix in women who are pregnant or breastfeeding. As the vaccine is not preventing infection, but reactivation of endogenous virus, women of child-bearing age who are immunocompromised and assessed to benefit from zoster vaccination, are recommended to receive Shingrix vaccine either: before a planned pregnancy, or as soon as practicable after birth.
Table. Vaccines that are not recommended in pregnancy
Vaccine Recommendation Comments
HPV (human papillomavirus) (inactivated viral vaccine) Not recommended

Clinical trials and limited data from observational studies where HPV vaccine was inadvertently given during pregnancy indicate that there is no increased risk of adverse effects on the fetus.36-38

If a woman becomes pregnant during a course of HPV vaccination, stop the course and complete it after birth.
Influenza (live attenuated viral vaccine) Not recommended

Inactivated influenza vaccines should be given in pregnancy instead of LAIV. However, there is no evidence of risk associated with LAIV in pregnancy. 

The live viruses in LAIV have been attenuated and adapted to cold, allowing them to only replicate at the lower temperatures found in the nasal passage. They cannot replicate efficiently anywhere else in the body and there is therefore no theoretical basis for concern about infection of the unborn foetus or the mother’s lungs. It is not necessary to specifically ask about or test for pregnancy when offering LAIV or to advise avoidance of pregnancy in those who have been recently vaccinated.
Yellow fever (live attenuated viral vaccine) Not recommended Advise pregnant women against going to rural areas where yellow fever is endemic. However, if travel to a country with a risk of yellow fever virus transmission is unavoidable, pregnant women should receive yellow fever vaccine.2,39,40 Many pregnant women have received yellow fever vaccine with no adverse outcomes,41 however there have been case reports of transmission to infants during pregnancy.
Table. Vaccines that are contraindicated in pregnancy: live attenuated vaccines
Vaccine Recommendation Comments
BCG (bacille Calmette–Guérin) (live attenuated bacterial vaccine) Contraindicated The risk is only hypothetical. BCG vaccine has not been shown to cause fetal damage.2,42
Oral typhoid (Vivotif oral) (live attenuated bacterial vaccine) Contraindicated No data are available on the safety of oral typhoid vaccine in pregnant women. However, because of the theoretical risk of using a live attenuated vaccine, pregnant women should receive inactivated typhoid Vi polysaccharide vaccine instead43 (see Table. Vaccines that are not routinely recommended in pregnancy: inactivated bacterial vaccines).
Oral cholera (Vaxchora) (live attenuated bacterial vaccine) Contraindicated No data are available on the safety of live oral cholera vaccine in pregnant women. However, because of the theoretical risk of using a live attenuated vaccine, pregnant women should receive inactivated oral cholera vaccine instead (see Table. Vaccines that are not routinely recommended in pregnancy: inactivated bacterial vaccines).
Japanese encephalitis (Imojev) (live attenuated viral vaccine) Contraindicated No data are available about using Imojev vaccine in pregnant or breastfeeding women. However, because of the theoretical risk of using a live attenuated vaccine, pregnant women should receive inactivated Japanese encephalitis (JEpect) instead. Women of child-bearing age should avoid pregnancy for 28 days after vaccination with Imojev.
MMR (measles-mumps-rubella) or MMRV (measles-mumps-rubella-varicella) (live attenuated viral vaccines) Contraindicated
  • The risk is only hypothetical. Despite concerns that live attenuated rubella vaccine virus might cause congenital abnormalities, pregnant women have received rubella vaccine (either monovalent or as MMR, and usually inadvertently) without harm to the fetus.44,45Even though rubella vaccine virus can infect the fetus, there is no evidence that it causes congenital rubella syndrome in infants.46 Women who receive rubella vaccine during pregnancy do not need to consider terminating the pregnancy.45
  • As a precautionary measure women of child-bearing age should avoid pregnancy for 28 days after vaccination.
  • All pregnant women are recommended to be tested for immunity to rubella. Susceptible women should receive rubella vaccine as soon as possible after birth and have their serological status checked after vaccination.
Rotavirus (live attenuated viral vaccine) Contraindicated Rotavirus vaccines are not registered or recommended for use in adolescents or adults.
Varicella (live attenuated viral vaccine) Contraindicated The risk of congenital varicella syndrome is only hypothetical. Newborns of women who have inadvertently been given varicella vaccine in early pregnancy have not had congenital varicella syndrome.47 Women of child-bearing age should avoid pregnancy for 28 days after vaccination.

Inactivated vaccines

Most inactivated vaccines are not routinely recommended for pregnant women.

Other than influenza, and diphtheria-, tetanus- and pertussis-containing vaccines, many inactivated vaccines are not routinely recommended during pregnancy, as a precaution. However, pregnancy is not an absolute contraindication to receiving these vaccines.

Fever associated with infection may be teratogenic. However, in clinical studies, most inactivated vaccines are not associated with increased rates of fever in adults (compared with placebo).48,49

Pregnant women are recommended to receive inactivated vaccines (other than influenza and dTpa) when the benefits of protection outweigh the risks.

Pregnant women can also reduce their risk by avoiding exposure to vaccine-preventable diseases during pregnancy. Strategies include changing travel plans, and avoiding high-risk behaviours or occupational exposures.

See:

Live attenuated viral vaccines

Live attenuated viral vaccines are contraindicated in pregnant women.

Live attenuated viral vaccines are contraindicated in pregnant women. This is because of the hypothetical risk of harm if the vaccine virus replicates in the fetus.

See Table. Vaccines that are contraindicated in pregnancy: live attenuated vaccines.

Inadvertently giving a live attenuated viral vaccine during pregnancy or shortly before pregnancy

The risk of adverse effects on the fetus following inadvertant administration of live attentuaated viral vaccine during pregnancy or shortly before pregnancy is a theoretical one.

The woman does not need to consider terminating the pregnancy if a live attenuated vaccine was inadvertently given and should be provided reassurance.2

Report inadvertent administration of a vaccine contraindicated in pregnancy to the Therapeutic Goods Administration. See Adverse events following immunisation for details on how to do this.

Post-marketing studies of pregnancy outcomes after vaccination are important to understand the safety profile of vaccines in pregnancy. Because of this, some vaccine manufacturers also have pregnancy registries, specific for their products, that accept reports of vaccines received during pregnancy.

An example is a registry in the United States for vaccines that contain varicella-zoster virus that was in place from March 1995 to October 2013 (see Varicella).

LAIV

Pregnant women should receive inactivated influenza vaccines. LAIV (Flumist) are not recommended in pregnancy. However, there is no evidence of risk associated with LAIV in pregnancy (see Influenza).

Yellow fever vaccine

Pregnant women are not recommended to receive the live attenuated yellow fever vaccine (Stamaril). However, travel to a country with a risk of yellow fever may be unavoidable. In this case, weigh the risks and benefits of yellow fever vaccination, and discuss other strategies to reduce the risk of acquiring yellow fever with the woman, such as avoiding mosquitoes (see Yellow fever).

See Table. Vaccines that are contraindicated in pregnancy: live attenuated vaccines.

Immunoglobulins as pre- or post-exposure prophylaxis

Immunoglobulins as pre- or post-exposure prophylaxis

Immunoglobulins for use as pre- or post-exposure prophylaxis are not routinely recommended for pregnant women. Limited data are available on the use of immunoglobulins during pregnancy. There are no known risks to the fetus if a pregnant woman receives immunoglobulin. Susceptible pregnant women at risk of acquiring, or being exposed to, certain vaccine-preventable diseases can receive immunoglobulins at any time during pregnancy.

See Table. Use of immunoglobulins as pre- or post-exposure prophylaxis during pregnancy.

Table. Use of immunoglobulins as pre- or post-exposure prophylaxis during pregnancy
Immunoglobulin Recommendation Comments
Pooled or hyperimmune immunoglobulins

Susceptible pregnant women exposed to the following can receive post-exposure immunoglobulin:

 Limited data are available. There is no known risk to the fetus from passive immunisation of pregnant women with immunoglobulins, given at any stage of pregnancy. For more details, see Passive immunisation and the relevant disease-specific chapters in this Handbook.

Contact between pregnant women and people who have recently received live vaccines

Household contacts of pregnant women should be age-appropriately vaccinated. It is safe for contacts of pregnant women to receive measles-, mumps-, rubella- and varicella-containing vaccines; zoster vaccine; LAIV and rotavirus vaccine.

Measles, mumps or rubella vaccine viruses are not transmitted from vaccinated household contacts to pregnant women.

Varicella-zoster vaccine virus (from people vaccinated with varicella vaccines) has an almost negligible risk of transmission. Advise vaccine recipients with a varicella-like rash to cover the rash if in contact with a pregnant woman.

There is a very small possibility that rotavirus vaccine viruses can be transmitted to pregnant contacts. However, the benefit of immunising infants to protect against rotavirus disease and, in turn, reduce the risk of rotavirus in household contacts far outweighs any theoretical risk to the pregnant woman or the fetus (see Rotavirus).

Use of immunosuppressive therapy during pregnancy

Inactivated vaccines and immunosuppressive therapy

Women who are receiving immunosuppressive therapy during pregnancy can also receive inactivated vaccines, where indicated. For more details, see:

This includes pregnant women who have received short-term antenatal corticosteroids — for example, after a preterm labour.

Infants born to mothers receiving immunosuppressive therapies during pregnancy should be administered with inactivated vaccines according to the recommended schedule. Cellular and humoral immunity may be affected in those infants and extra inactivated vaccine doses may be needed. However, existing studies show adequate responses to routinely recommended inactivated vaccines in these infants,50-52 even if the infant had measurable drug levels, with no major adverse events reported.

For detailed guidance on live and non-live vaccine recommendations for affected infants, see:

Live attenuated vaccines and immunosuppressive therapy

Certain immunosuppressive therapies, such as anti-T/B cell therapies, tumour necrosis factor (TNF)-alpha inhibitors, used to manage a medical condition in a pregnant woman may cross the placenta and be detectable in the infant. This is especially true if given during the 3rd trimester.53-55

See also Infants exposed to immunosuppressive therapy in utero or through breastmilk and Table. Administration of non-live and live vaccines to infants exposed to biological immunosuppressive therapies in utero.

BCG vaccine

Infants exposed to immunosuppressive therapies in utero should not receive BCG vaccine until they are at least 6 months of age (see also Tuberculosis). This is because the infant may have a reduced immune response to vaccination, and vaccine virus/bacteria replication and related adverse effects could increase.56 Although no specific intervals are indicated, the infant should be 6 months old before receiving a BCG vaccine.57,58

Rotavirus vaccine

Most infants exposed to biological immunosuppressive therapies in utero can safely receive rotavirus vaccine, except those exposed to anti-CD20 therapies such as rituximab (see also Rotavirus).

Infants exposed to TNF-alpha inhibitors and other biological therapies (such as eculizumab, belimumab, vedolizumab, natalizumab) in utero have safely received oral rotavirus vaccine without significant adverse events.59-67

Notably, infants exposed to anti-CD20 therapies (such as rituximab) should not receive oral rotavirus vaccine.68-71 Rituximab can cross the placenta, and has been associated with low or absent B-cells in infants exposed in the 2nd or 3rd trimester in utero.69,71 The potential immunosuppressive effects of rituximab exposure last beyond the upper age limit for administration of rotavirus vaccine (see Table. Upper age limits for dosing of oral rotavirus vaccines).

Other vaccines

Although safety data are limited, live vaccines can be considered for infants aged <12 months who were exposed to biological immunosuppressive therapies in utero. Examples are measles-containing vaccines or yellow fever vaccine before overseas travel. Consult a specialist if unsure.

Infants exposed to biological therapies in utero can safely receive all scheduled live vaccines at ≥12 months of age, including MMR (measles-mumps-rubella) and MMRV (measles-mumps-rubella-varicella) vaccines.

For more details, see Infants exposed to immunosuppressive therapy in utero or through breastmilk.

Women who are breastfeeding

Vaccination is never contraindicated in breastfeeding women. For most vaccines, an infant’s immune response to vaccination in relation to breastfeeding has been considered. In general, breastfeeding does not adversely affect immunisation, and breastfeeding is not a contraindication for any vaccines recommended in infants.

Rubella vaccine virus

Rubella vaccine virus may be secreted in human breast milk, and the virus can be transmitted to breastfed infants. However, if an infant becomes infected, they have no symptoms or only mild symptoms.72-74

Hepatitis B virus

Infants born to mothers who are positive for hepatitis B surface antigen (HBsAg) can be breastfed, as long as the infant is appropriately immunised at birth. Although studies have found hepatitis B virus in the breast milk of mothers with hepatitis B virus infection, breastfeeding poses no additional risk of virus transmission, compared with formula feeding, in vaccinated infants.75

Yellow fever vaccine

Breastfeeding women should not receive yellow fever vaccine unless the mother has a high risk of acquiring yellow fever, or cannot avoid or postpone travel.76,77 Although extremely rare, there have been several case reports of probable transmission of the yellow fever vaccine virus to infants through breast milk.76,77

References

  1. Duque J, Howe AS, Azziz-Baumgartner E, Petousis-Harris H. Multi-decade national cohort identifies adverse pregnancy and birth outcomes associated with acute respiratory illness hospitalisations during the influenza season. Influenza Other Respir Viruses 2023;17:e13063.
  2. Kong KL, Krishnaswamy S, Giles ML. Maternal vaccinations. Aust J Gen Pract 2020;49:630-5.
  3. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. The Lancet 2014;384:1521-8.
  4. Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014;311:1760-9.
  5. Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ 2014;349:g4219.
  6. Shakib JH, Korgenski K, Sheng X, et al. Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. Journal of Pediatrics 2013;163:1422-6.
  7. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. American Journal of Obstetrics and Gynecology 2011;204:334.e1-5.
  8. Zheteyeva YA, Moro PL, Tepper NK, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. American Journal of Obstetrics and Gynecology 2012;207:59.e1-7.
  9. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA 2014;312:1897-904.
  10. Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. New England Journal of Medicine 2023;388:1451-64.
  11. Gentile A, Juárez MDV, Lucion MF, et al. Maternal Immunization With RSVpreF Vaccine: Effectiveness in Preventing Respiratory Syncytial Virus-associated Hospitalizations in Infants Under 6 Months in Argentina: Multicenter Case-control Study. Pediatric Infectious Disease Journal 2025;44:988-94.
  12. Pérez Marc G, Vizzotti C, Fell DB, et al. Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study. The Lancet Infectious Diseases 2025;25:1044-54.
  13. McLachlan I, Robertson C, Morrison KE, et al. Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case-control study and cohort analysis. The Lancet Infectious Diseases 2025.
  14. Williams TC, Marlow R, Cunningham S, et al. Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study. The Lancet Child and Adolescent Health 2025;9:655-62.
  15. Dieussaert I, Hyung Kim J, Luik S, et al. RSV prefusion F protein-based maternal vaccine - preterm birth and other outcomes. New England Journal of Medicine 2024;390:1009-21.
  16. World Health Organization (WHO). Tetanus vaccines: WHO position paper – February 2017. Weekly Epidemiological Record 2017;92:53-76.
  17. Czeizel AE, Rockenbauer M. Tetanus toxoid and congenital abnormalities. International Journal of Gynaecology and Obstetrics 1999;64:253-8.
  18. Silveira CM, Cáceres VM, Dutra MG, Lopes-Camelo J, Castilla EE. Safety of tetanus toxoid in pregnant women: a hospital-based case–control study of congenital anomalies. Bulletin of the World Health Organization 1995;73:605-8.
  19. World Health Organization (WHO). Cholera vaccines: WHO position paper – August 2017. Weekly Epidemiological Record 2017;92:477-98.
  20. Mulholland K, Suara RO, Siber G, et al. Maternal immunization with Haemophilus influenzae type b polysaccharide–tetanus protein conjugate vaccine in The Gambia. JAMA 1996;275:1182-8.
  21. Harrison LH, Granoff DM, Pollard AJ. Meningococcal capsular group A, C, W, and Y conjugate vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin's vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018.
  22. World Health Organization (WHO). Meningococcal vaccines: WHO position paper, November 2011. Weekly Epidemiological Record 2011;86:521-39.
  23. Dunbar M, Moberley S, Nelson S, Leach AJ, Andrews R. Clear not simple: an approach to community consultation for a maternal pneumococcal vaccine trial among Indigenous women in the Northern Territory of Australia. Vaccine 2007;25:2385-8.
  24. Centers for Disease Control and Prevention (CDC). Guidelines for vaccinating pregnant women. (Accessed Apr 2018). https://www.cdc.gov/vaccines/pregnancy/hcp/guidelines.html
  25. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. New England Journal of Medicine 2021;384:2273-82.
  26. World Health Organization (WHO). WHO position paper on hepatitis A vaccines – June 2012. Weekly Epidemiological Record 2012;87:261-76.
  27. World Health Organization (WHO). Hepatitis B vaccines: WHO position paper – July 2017. Weekly Epidemiological Record 2017;92:369-92.
  28. US Food and Drugs Administration. JYNNEOS - full prescribing information package insert. 2018. (Accessed July 17). https://www.fda.gov/media/131078/download
  29. World Health Organization (WHO). Japanese encephalitis vaccines: WHO position paper – February 2015. Weekly Epidemiological Record 2015;90:69-87.
  30. Chutivongse S, Wilde H, Benjavongkulchai M, Chomchey P, Punthawong S. Postexposure rabies vaccination during pregnancy: effect on 202 women and their infants. Clinical Infectious Diseases 1995;20:818-20.
  31. Varner MW, McGuinness GA, Galask RP. Rabies vaccination in pregnancy. American Journal of Obstetrics and Gynecology 1982;143:717-8.
  32. Sudarshan MK, Giri MS, Mahendra BJ, et al. Assessing the safety of post-exposure rabies immunization in pregnancy. Human Vaccines 2007;3:87-9.
  33. Chabala S, Williams M, Amenta R, Ognjan AF. Confirmed rabies exposure during pregnancy: treatment with human rabies immune globulin and human diploid cell vaccine. American Journal of Medicine 1991;91:423-4.
  34. Centers for Disease Control and Prevention (CDC), Manning SE, Rupprecht CE, et al. Human rabies prevention – United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR. Recommendations and Reports 2008;57(RR-3):1-28.
  35. World Health Organization (WHO). Rabies vaccines: WHO position paper – April 2018. Weekly Epidemiological Record 2018;93:201-19.
  36. World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, May 2017. Weekly Epidemiological Record 2017;92:241-68.
  37. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstetrics and Gynecology 2009;114:1179-88.
  38. Moreira ED, Jr., Block SL, Ferris D, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics 2016;138:e20154387.
  39. Suzano CE, Amaral E, Sato HK, Papaiordanou PM, Campinas Group on Yellow Fever Immunization during Pregnancy. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006;24:1421-6.
  40. Cavalcanti DP, Salomão MA, Lopez-Camelo J, Pessoto MA, Campinas Group of Yellow Fever Immunization during Pregnancy. Early exposure to yellow fever vaccine during pregnancy. Tropical Medicine and International Health 2007;12:833-7.
  41. World Health Organization (WHO). Vaccines and vaccination against yellow fever: WHO position paper – June 2013. Weekly Epidemiological Record 2013;88:269-83.
  42. World Health Organization. BCG vaccines: WHO position paper – February 2018. Weekly Epidemiological Record 2018;93:73-96.
  43. World Health Organization (WHO). Typhoid vaccines: WHO position paper – March 2018. Weekly Epidemiological Record 2018;93:153-72.
  44. Centers for Disease Control and Prevention (CDC). Rubella vaccination during pregnancy – United States, 1971–1988. MMWR. Morbidity and Mortality Weekly Report 1989;38:289-93.
  45. Hamkar R, Jalilvand S, Abdolbaghi MH, et al. Inadvertent rubella vaccination of pregnant women: evaluation of possible transplacental infection with rubella vaccine. Vaccine 2006;24:3558-63.
  46. Bar-Oz B, Levichek Z, Moretti ME, et al. Pregnancy outcome following rubella vaccination: a prospective controlled study. American Journal of Medical Genetics 2004;130A:52-4.
  47. Marin M, Willis ED, Marko A, et al. Closure of varicella-zoster virus-containing vaccines pregnancy registry – United States, 2013. MMWR. Morbidity and Mortality Weekly Report 2014;63:732-3.
  48. Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. Epidemiology 2005;16:216-9.
  49. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Maternal fever and birth outcome: a prospective study. Teratology 1998;58:251-7.
  50. Gisbert JP, Chaparro M. Vaccines in children exposed to biological agents in utero and/or during breastfeeding: Are they effective and safe? Journal of Crohn's and Colitis 2023;17:995-1009.
  51. Beaulieu DB, Ananthakrishnan AN, Martin C, et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol 2018;16:99-105.
  52. Berkhout A, Clark JE, Wen SC. In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration. Expert Review of Vaccines 2019;18:495-504.
  53. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clinical and Developmental Immunology 2008;2008:271363.
  54. Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Annals of the Rheumatic Diseases 2009;68:1793-4.
  55. Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Alimentary Pharmacology and Therapeutics 2011;33:1053-8.
  56. Cheent K, Nolan J, Shariq S, et al. Case report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. Journal of Crohn's and Colitis 2010;4:603-5.
  57. Luu M, Benzenine E, Barkun A, et al. Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNFα agents: a French nationwide population-based cohort. Alimentary Pharmacology and Therapeutics 2019;50:1181-8.
  58. Park SH, Kim HJ, Lee CK, et al. Safety and optimal timing of BCG vaccination in infants born to mothers receiving anti-TNF therapy for inflammatory bowel disease. Journal of Crohn's and Colitis 2020;14:1780-4.
  59. Jürgens M, Brand S, Filik L, et al. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Inflammatory Bowel Diseases 2010;16:1634-6.
  60. Nielsen OH, Loftus EV, Jr., Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Medicine 2013;11:174.
  61. Bitter H, Bendvold AN, Østensen ME. Lymphocyte changes and vaccination response in a child exposed to belimumab during pregnancy. Annals of the Rheumatic Diseases 2018;77:1692-3.
  62. Moens A, van Hoeve K, Humblet E, et al. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with Vedolizumab. Journal of Crohn's and Colitis 2019;13:12-8.
  63. Hallstensen RF, Bergseth G, Foss S, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology 2015;220:452-9.
  64. Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol 2014;71:891-5.
  65. Schneider H, Weber CE, Hellwig K, Schroten H, Tenenbaum T. Natalizumab treatment during pregnancy - effects on the neonatal immune system. Acta Neurologica Scandinavica 2013;127:e1-4.
  66. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016;151:110-9.
  67. Esteve-Solé A, Deyà-Martínez À, Teixidó I, et al. Immunological changes in blood of exposed to anti-TNF-α during pregnancy. Frontiers in immunology 2017;8:1123.
  68. Fitzpatrick T, Alsager K, Sadarangani M, et al. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. The Lancet Child and Adolescent Health 2023;7:648-56.
  69. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken) 2023;75:449-64.
  70. Zerbo O, Modaressi S, Goddard K, et al. Safety of live-attenuated vaccines in children exposed to biologic response modifiers in utero. Pediatrics 2022;150.
  71. Dinelli MIS, Dos Santos AMN, Weckx LY, de Moraes-Pinto MI. Safe administration of rotavirus vaccine in a cohort of infants exposed to immunosuppressive drugs during gestation. Transpl Infect Dis 2018;20:e12951.
  72. Klein EB, Byrne T, Cooper LZ. Neonatal rubella in a breast-fed infant after postpartum maternal infection. Journal of Pediatrics 1980;97:774-5.
  73. Landes RD, Bass JW, Millunchick EW, Oetgen WJ. Neonatal rubella following postpartum maternal immunization. Journal of Pediatrics 1980;97:465-7.
  74. Losonsky GA, Fishaut JM, Strussenberg J, Ogra PL. Effect of immunization against rubella on lactation products. II. Maternal-neonatal interactions. Journal of Infectious Diseases 1982;145:661-6.
  75. Zheng Y, Lu Y, Ye Q, et al. Should chronic hepatitis B mothers breastfeed? A meta analysis. BMC Public Health 2011;11:502.
  76. Centers for Disease Control and Prevention (CDC). Transmission of yellow fever vaccine virus through breast-feeding – Brazil, 2009. MMWR. Morbidity and Mortality Weekly Report 2010;59:130-2.
  77. Kuhn S, Twele-Montecinos L, MacDonald J, Webster P, Law B. Case report: Probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ Canadian Medical Association Journal 2011;183:E243-5.

Page history

Last updated
Last reviewed

Updated to include new information regarding LAIV. Pregnant women should continue to receive IIV rather than LAIV.

Updated advice on revaccination with RSV Abrysvo in each pregnancy to align with RSV chapter.

Minor editorial updates relating to wording around the upper gestational age for the administration of Abrysvo.

Addition of text to clarify guidance of non-live vaccine administration to infants born to mothers receiving immunosuppressive therapies during pregnancy to align with the updated guidance in “Infants exposed to immunosuppressive therapy in utero or through breastmilk” in Vaccination for people who are immunocompromised chapter.

Addition of text to provide guidance on live vaccine administration to infants born to mothers who received biological immunosuppressive therapies during pregnancy, particularly to rotavirus vaccine recommendations, to align with the updated guidance in “Infants exposed to immunosuppressive therapy in utero or through breastmilk” in Vaccination for people who are immunocompromised chapter.

Updates to reflect new recommendations for RSV vaccine Abrysvo in pregnant women. 

Updates to reflect the availability of the mpox vaccine, JYNNEOS. Updates to include detail on JYNNEOS use in pregnancy, if indicated, as post-exposure preventive vaccination.  

Update to Table. Vaccines that are contraindicated in pregnancy: live attenuated vaccines to reflect the availability of oral cholera vaccine.

Minor updates to clinical guidance including inclusion of COVID-19 vaccine in Table. Vaccines that are not routinely recommended in pregnancy: inactivated viral vaccines.

Updates to reflect addition of 20vPCV in Table. Vaccines that are not routinely recommended in pregnancy: inactivated bacterial vaccines.

Updates to Table. Vaccines that are not routinely recommended in pregnancy: inactivated bacterial vaccines to include 15-valent pneumococcal conjugate vaccine.

Updated guidance to include recombinant zoster vaccine (Shingrix) in Table. Vaccines that are not routinely recommended in pregnancy: inactivated viral vaccines.

Guidance on vaccination of infants exposed to bDMARDs (biological disease-modifying anti-rheumatic drugs) in utero has been updated. Infants born to mothers who received bDMARDs during pregnancy are not recommended to receive rotavirus vaccine. Drug levels may be measured to guide decision-making.

Updated to include new information regarding LAIV. Pregnant women should continue to receive IIV rather than LAIV.

Updated advice on revaccination with RSV Abrysvo in each pregnancy to align with RSV chapter.

Minor editorial updates relating to wording around the upper gestational age for the administration of Abrysvo.

Addition of text to clarify guidance of non-live vaccine administration to infants born to mothers receiving immunosuppressive therapies during pregnancy to align with the updated guidance in “Infants exposed to immunosuppressive therapy in utero or through breastmilk” in Vaccination for people who are immunocompromised chapter.

Addition of text to provide guidance on live vaccine administration to infants born to mothers who received biological immunosuppressive therapies during pregnancy, particularly to rotavirus vaccine recommendations, to align with the updated guidance in “Infants exposed to immunosuppressive therapy in utero or through breastmilk” in Vaccination for people who are immunocompromised chapter.

Updates to reflect new recommendations for RSV vaccine Abrysvo in pregnant women. 

Updates to reflect the availability of the mpox vaccine, JYNNEOS. Updates to include detail on JYNNEOS use in pregnancy, if indicated, as post-exposure preventive vaccination.  

Update to Table. Vaccines that are contraindicated in pregnancy: live attenuated vaccines to reflect the availability of oral cholera vaccine.

Minor updates to clinical guidance including inclusion of COVID-19 vaccine in Table. Vaccines that are not routinely recommended in pregnancy: inactivated viral vaccines.

Updates to reflect addition of 20vPCV in Table. Vaccines that are not routinely recommended in pregnancy: inactivated bacterial vaccines.

Updates to Table. Vaccines that are not routinely recommended in pregnancy: inactivated bacterial vaccines to include 15-valent pneumococcal conjugate vaccine.

Updated guidance to include recombinant zoster vaccine (Shingrix) in Table. Vaccines that are not routinely recommended in pregnancy: inactivated viral vaccines.

Guidance on vaccination of infants exposed to bDMARDs (biological disease-modifying anti-rheumatic drugs) in utero has been updated. Infants born to mothers who received bDMARDs during pregnancy are not recommended to receive rotavirus vaccine. Drug levels may be measured to guide decision-making.

Is there anything wrong with this page?

Printed content may be out of date. For up to date information, always refer to the digital version:

https://immunisationhandbook.health.gov.au/contents/vaccination-for-special-risk-groups/vaccination-for-women-who-are-planning-pregnancy-pregnant-or-breastfeeding
Link copied

Link, share or bookmark directly to this section of the page.